TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Natural Sciences

    Clinical Liver Disease

    Clinical Liver Disease (CLD), an official digital learning resource of The American Association for the Study of Liver Diseases is an interactive, up-to-date source of education, designed for physicians and healthcare providers caring for the patient with liver disease. CLD provides current and clinically relevant information through educational interventions every two months.

    Advertise

    Copyright: © Copyright 2012

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue? - Mauro Viganò and Pietro Lampertico – Article Reading Jul 07, 2013
    Show notes

    Drs. Vigano and Lampertico weigh in on the nucleos(t)ide analogues (NAs)-pegylated interferon (PEG-IFN) debate, addressing first line therapy selection, monitoring of the patient treated with NAs, and when if ever it is appropriate to stop treatment.

    Solid organ transplantation and hepatitis B virus - Federico Villamil and Fernando Cairo – Article Reading. Jul 07, 2013
    Show notes

    Drs. Villamil and Cairo review the best available evidence on managing the HBV patient who has received a solid organ transplantation. For liver transplant patients, the authors address whether there is a role for hepatitis B immunoglobulin, whether antiviral monotherapy sufficient, and how best to manage liver transplantations from antibody to hepatitis B core antigen (anti-HBc) positive donors. In the kidney transplant patient, Drs. Villamil and Cairo discuss kidney transplant in HBsAg-positive patients, as well as kidney transplants from anti-HBc positive donors.

    Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice - Grace Lai-Hung Wong and Henry Lik-Yuen Chan – Article Reading Jul 07, 2013
    Show notes

    Quantitative Hepatitis B Surface Antigen provides information concerning disease activity over and above an estimation of viral replication. It is an indispensable tool in the clinical assessment and management of chronic hepatitis B viral infection. Drs. Wong and Chan highlight what the clinician needs to know.

    Predicting clinical outcome in a patient with chronic hepatitis B virus infection - Hwai-I Yang and Pei-Jer Chen – Article Reading Jul 07, 2013
    Show notes

    Hepatitis B can lead to several severe clinical outcomes, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma. While the establishment of a risk prediction tool for various clinical outcomes for patients with HBV is still in a preliminary phase, the use and refinement of these prediction tools may supply HBV patients with a comprehensive individualized management measure based on the risk perspectives. Drs. Yang and Chen explain..

    What primary care providers need to know about hepatocellular carcinoma - Parul Dureja Agarwal – Article Reading Jul 07, 2013
    Show notes

    Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a major global health problem. Dr. Agarwal discusses risk factors, surveillance, and management strategies for the primary care provider.

    Histopathologic features of hepatocellular carcinoma - Elizabeth M. Brunt – Article Reading Jul 07, 2013
    Show notes

    Recent studies suggest that for optimum clinical outcomes, management of hepatocellular carcinoma necessitates the most reliable classification of tumors, including histopathologic evaluation. Dr. Brunt discusses current criteria, useful immunohistochemistry stains, and differential diagnostic considerations for hepatocellular carcinoma..

    Systemic targeted therapy beyond sorafenib - Roniel Cabrera – Article Reading Jul 07, 2013
    Show notes

    Dr. Cabrera discusses the planned, ongoing, and completed clinical trials for advanced HCC. A brief overview of recent failures and ongoing clinical studies with emerging molecular targeted agents along with future perspectives is covered.

    New issues in the pathogenesis of hepatocellular carcinoma: Applying insights from next-generation DNA sequencing technologies to improve therapy for hepatocellular carcinoma - Roongruedee Chaiteerakij and Lewis R. Roberts – Article Reading Jul 07, 2013
    Show notes

    Drs. Chaiteerakij and Roberts summarize the current understanding of the pathogenesis of hepatocellular carcinoma and HCC tumor biology gained from recent studies using NGS technology to analyze HCC tumors. They also discuss potential strategies for harnessing this new information to improve therapy for patients with advanced HCC.

    Natural history and staging for hepatocellular carcinoma - Alejandro Forner, Carlos Rodríguez-Lopez and María Reig – Article Reading Jul 07, 2013
    Show notes

    The Barcelona Clinic Liver Cancer (BCLC) staging system was designed to stratify patients according to outcome while simultaneously linking it with treatment indication. Drs. Forner, Rodriguez-Lopez, and Reig highlight the advantages to the BCLC staging system, while also addressing areas for further refinement.

    Risk factors for hepatocellular carcinoma - D. Alan Herbst and K. Rajender Reddy – Article Reading. Jul 07, 2013
    Show notes

    Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide, and each year, approximately 750,000 new cases are diagnosed. As the incidence of liver cancer continues to rise, effective surveillance programs are necessary in order to maximize patient outcomes which require effective identification of HCC risk factors.

    Previous 1 130 131 132 133 134 138 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    Radiolab

    2

    Radiolab Documentary
    BrainStuff

    3

    BrainStuff Natural Sciences
    StarTalk with Neil deGrasse Tyson

    4

    StarTalk with Neil deGrasse Tyson Games & Hobbies
    Radiolab

    5

    Radiolab Documentary
    Stuff To Blow Your Mind

    6

    Stuff To Blow Your Mind Life Sciences
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights